Literature DB >> 7504573

Pharmacological profile of risperidone.

L Ereshefsky1, S Lacombe.   

Abstract

The pharmacodynamics and pharmacokinetics of risperidone, an important atypical antipsychotic drug with potent serotonin-5-HT2 and dopamine-D2 receptor blocking effects, are presented. The pharmacology of atypical versus typical antipsychotic drugs is discussed in the contest of a pathophysiological conceptualization for schizophrenia which incorporates a parkinsonian model with an important role for serotonin and excitatory amino acid neurotransmission. In the normal therapeutic dose range, risperidone displays dose-linear pharmacokinetics in humans and reaches steady-state within 24 hours. Risperidone metabolism yields a active metabolite, 9-OH-risperidone, that has a similar pharmacological profile to the patient compound and therefore contributes to the clinical efficacy of the drug.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504573

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  18 in total

Review 1.  Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia.

Authors:  N Bhana; C M Spencer
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

Review 2.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets.

Authors:  Ying Chen; Yang Deng; Miao Yan; Zhenyan Hou; Yao Li; Bikui Zhang; Hualin Cai
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-08       Impact factor: 2.441

Review 4.  The Canadian experience with risperidone for the treatment of schizophrenia: an overview.

Authors:  M Iskedjian; M Hux; G J Remington
Journal:  J Psychiatry Neurosci       Date:  1998-09       Impact factor: 6.186

Review 5.  New atypical antipsychotics. Experience and utility in the elderly.

Authors:  R A Sweet; B G Pollock
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

Review 6.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

7.  Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.

Authors:  J J Miceli; K D Wilner; R A Hansen; A C Johnson; G Apseloff; N Gerber
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

8.  Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.

Authors:  Jessica A Knight; Carol Smith; Nicole Toohey; Michael T Klein; Milt Teitler
Journal:  Mol Pharmacol       Date:  2008-11-07       Impact factor: 4.436

Review 9.  Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.

Authors:  Hans-Jürgen Möller
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Authors:  Pierre Chue
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.